


AUGUST 2021

Investor Presentation





our langose





2

Disclosures

Special Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position; business strategy; the market growth for our product; our ability to meet our goals related to the market position of our product; the potential market acceptance, demand market size, adoption rate, revenue expectations and future results of our product and related loyalty programs, are forward-looking statements. Forward-looking statements are based on current estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Forwardlooking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Other factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include uncertainties associated with the success of the launch of Jeuveau[®], customer and consumer adoption of the product, competition and market dynamics, our ability to comply with our settlement agreement with Allergan and Medytox, and our ability to maintain regulatory approval of Jeuveau[®] and other risks described in the section entitled "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 as filed with the Securities and Exchange Commission on August 4, 2021 which is available online at www.sec.gov. All written and verbal forward-looking statements attributable to our Company or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. We may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. The forward-looking statements in this presentation represent our views as of the date of this presentation. We anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this presentation.

Certain of the industry, statistical and market data in this presentation was obtained from our own internal estimates and research as well as from industry and general publications and research, surveys and studies conducted by third parties. All of the market data used in this presentation involves a number of assumptions and limitations. While we believe that the information from these industry publications, surveys and studies is reliable, the industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important factors, which could cause results to differ materially from those expressed in the estimates made by third parties and by us. Evolus™, Jeuveau[®] and Evolux[®] are three of our trademarks that are used in this presentation.

Our financial results are prepared in accordance with Generally Accepted Accounting Principles ("GAAP"). This presentation includes non-GAAP financial measures. Our reconciliations of non-GAAP financial measures to GAAP financial measures are located at the end of this presentation. These non-GAAP financial measures should not be considered as an alternative to GAAP financial measures.



3

Investment Highlights



Commercial company operating in the aesthetic neurotoxin market, which is the largest market segment of the fast-growing \$12B medical aesthetics market¹



Launched the first "cash pay", aesthetic only, U.S. neurotoxin in May 2019



Highly experienced management team with a track record of success in gaining approvals and commercializing several of the largest aesthetic products



Lead commercial product, Jeuveau[®], positioned against a younger millennial demographic with a focus on technology, creating unique differentiation

1. The Global Aesthetic Market Study (September 2020). Medical Insights (<u>www.miinews.com</u>)

2. Cosmetic Neurotoxin Market Study (January 2021). Medical Insights (<u>www.miinews.com</u>)



Growing revenue base - achieved U.S. Jeuveau[®] net revenue of \$56.5M in 2020 in the \$1.3 billion U.S. neurotoxin market²



Approved & launched in Canada with European launch anticipated in early 2022 and Australian filing under preparation



Approximately \$132 million cash at 6/30/21





Highly Experienced Leadership Team

David Moatazedi PRESIDENT AND CEO Lauren Silvernail CFO AND EVP, CORPORATE DEVELOPMENT Rui Avelar, MD CHIEF MEDICAL OFFICER AND HEAD OF R&D






Jeff Plumer GENERAL COUNSEL

Kurt Knab VICE PRESIDENT, SALES





Singularity of Focus



- 1. U.S Market Size. Cosmetic Neurotoxin Market Study (January 2021). Medical Insights (www.miinews.com)
- 2. Evolus Market Research Study 2019. (N = 22,866 nationally representative online respondents).
- 3. JET Study Data, 2019.
- 4. Evolus Millennial Mindset Study, 2018. (N = 27,673).

Direct to Millennial (ages 25-39)

Millennials Represent 39%³ of Jeuveau[®] Patients

51% bothered by facial lines and wrinkles⁴

64%

worry about getting or worsening facial lines and wrinkles in the future⁴

70%

willing to spend money on maintaining or improving facial appearance⁴








The Jeuveau[®] Difference



Value Proposition

Technology/Digital App



Consumer Experience



evolux[•]: Modern Loyalty





7

Co-Branded Media Campaigns Drive Jeuveau® Awareness

>500 Accounts Earned **Co-Branded Advertising To Date**








Science and Clinical Overview




Jeuveau[®]: A Neurotoxin by Design

State-of-the-Art Manufacturing with Patented Hi-Pure[™] Technology



900 kDa prabotulinumtoxinA Purification method: Crystallization Finishing method: Vacuum dried



0.5 mg Human Serum Albumin

0.9 mg salt

Jeuveau® Global Clinical Program: >2,100 Patients Across Five Clinical Trials

U.S. Phase III: Jeuveau® vs Placebo

- Two identical Phase III safety and efficacy studies (EV-001 & EV-002)
 Multicenter, randomized, double-blind, placebo controlled, single dose
 Placebo-controlled, superiority design
- •EV-001 n = 330
- •EV-002 n = 324

Head-to-head EU/Canada Phase III trial: Jeuveau® vs Botox

EU / Canada Phase III safety and efficacy (EVB-003) •Multicenter, randomized, double-blind, placebo & active controlled, single dose •Active control, non-inferiority design versus Botox •n = 540


Jeuveau[®] Safety Studies


- •U.S. Phase II Long-Term Safety Studies (EV-004 & EV-006)
- •One-year multicenter, non-randomized, open label, multiple dose
- •EV-004 n = 352
- •EV-006 n = 570





Jeuveau[®]: Designed To Compete Clinically With the Market Leader





Safety Profile - Adverse Events

EU PIII EVB-003									
	Placebo	Onabot	Prabot						
All	32.7%	41.9%	37.6%						
Related	4.1%	14.6%	15.5%						

Serious Adverse Effects

Drug Related

• None

Other AE's of Interest

- Ptosis (related)
- Eyelid Jeuveau 1.6%, Botox 0%
- Eyebrow Jeuveau 0%, Botox 0.4%





11

Evolus Performance Mathias



Record YTD 2021 Sales Demonstrates Strong Demand for Jeuveau[®]










Performance Metrics Illustrate Sustained Growth¹




1. Evolus measured metrics.

2. Cumulative accounts purchasing as of period end since May 2019 launch.

3. Jeuveau[®] period end re-order rates since its May 2019 launch.

Consumer registration has increased 66% since YE 2020



Re-order Rates³

Evolus Rewards: Cumulative Patients Registered







evolus.com





Strong Financial Performance

(in millions, except gross margin)	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021	Q2 20
Net Revenue	-	\$2.3	\$13.2	\$19.5	\$34.9	\$10.5	\$7.8	\$17.7	\$20.6	\$56.5	\$12.2	\$2
Gross Profit Margin	-	40%	66%	78%	69%	53%	66%	68%	61%	62%	262%	54
Adjusted Gross Profit Margin ¹	-	71%	72%	81%	77%	60%	75%	73%	65%	68%	60%	5
GAAP Operating Expense ²	\$25.3	\$38.3	\$38.3	\$32.0	\$133.9	\$27.9	\$26.7	\$26.4	\$128.6	\$209.6	\$4.2	\$14
Non-GAAP Operating Expense ²	\$17.9	\$33.6	\$32.8	\$31.8	\$116.1	\$33.4	\$20.2	\$24.2	\$32.8	\$110.6	\$24.8	\$3
GAAP Net Income (Loss)	(\$11.0)	(\$37.6)	(\$27.0)	(\$14.5)	(\$90.0)	(\$19.7)	(\$21.1)	(\$11.5)	(\$110.7)	(\$163.0)	\$6.4	(\$15
Non-GAAP Net (Loss) ²	(\$3.6)	(\$32.9)	(\$21.5)	(\$14.3)	(\$72.2)	(\$25.2)	(\$14.7)	(\$9.2)	(\$14.9)	(\$64.0)	(\$14.2)	(\$9
Cash, cash equivalents and short-term investments	\$133.7	\$99.9	\$74.0	\$129.8	\$129.8	\$99.6	\$84.8	\$110.1	\$107.7	\$107.7	\$22.2 ³	\$13
Weighted-Average Shares Outstanding	27.3	27.4	27.5	30.7	28.2	33.7	33.7	33.7	33.7	33.7	37.1	

1. Defined as total net revenues less product cost of sales, excluding amortization of intangible assets, and a \$25.5 million settlement payment from Daewoong in Q1 2021, as a percentage of net revenues. 2. Reconciliation of GAAP to non-GAAP financial measures included on slides 18-19.

3. March 31, 2021 pro forma cash balance was \$140 million, including a \$25.5 million settlement payment and \$92.1 million proceeds from an equity offering.




















Gross Profit Margin to Adjusted Gross Profit Margin

Evolus has presented Adjusted Gross Profit and Adjusted Gross Profit Margin. Adjusted Gross Profit is calculated as gross profit excluding one-time settlement payment from Daewoong and amortization of intangible asset. Adjusted Gross Profit Margin is defined as Adjusted Gross Profit as a percentage of total net revenues.


Management believes that adjusted gross profit margin is an important measure for investors because management uses adjusted gross profit margin as key performance indicator to evaluate the profitability of sales without giving effect to costs that are not core to our cost of sales, such the settlement payment from Daewoong and amortization of intangible asset. The company's definitions of Adjusted Gross Profit and Adjusted Gross Profit Margin have limitations as analytical tools and may differ from other companies reporting similarly named measures. Adjusted Gross Profit and Adjusted Gross Profit Margin should be considered in addition to results prepared in accordance with GAAP but should not be considered a substitute for or superior to GAAP results.

(in millions, except gross profit margin and adjusted gross profit margin)	Q1 2019
Total Net Revenue	-
Product Cost of Sales (Excludes Amortization of Intangible Assets)	-
Settlement Payment from Daewoong	-
Amortization of Distribution Right Intangible Asset	\$0.5
Gross Profit	-
Gross Profit Margin	-
Adjustments:	
Settlement Payment from Daewoong	-
Amortization of Distribution Right Intangible Asset	\$0.5
Adjusted Gross Profit	-
Adjusted Gross Profit Margin	-

Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021	
\$2.3	\$13.2	\$19.5	\$34.9	\$10.5	\$7.8	\$17.7	\$20.6	\$56.5	\$12.2	
\$0.7	\$3.7	\$3.6	\$8.0	\$4.2	\$1.9	\$4.9	\$7.3	\$18.3	\$4.9	
-	-	-	_	-	-	-	-	-	(\$25.5)	

									(\$20.0)	
\$0.7	\$0.7	\$0.7	\$2.7	\$0.7	\$0.7	\$0.7	\$0.8	\$3.0	\$0.7	
\$0.9	\$8.7	\$15.1	\$24.2	\$5.5	\$5.1	\$12.1	\$12.5	\$35.3	\$32.1	
40%	66%	78%	69%	53%	66%	68%	61%	62%	262%	
-	-	-	-	-	-	-	-	-	(\$25.5)	
\$0.7	\$0.7	\$0.7	\$2.7	\$0.7	\$0.7	\$0.7	\$0.8	\$3.0	\$0.7	
										1

\$15.8 \$1.7 \$9.4 \$26.9 \$6.3 \$5.9 \$12.8 \$13.3 \$38.2 \$7.2 71% 72% 81% 60% 75% 73% 65% 68% 60% 77%






GAAP to Non-GAAP Reconciliation

Evolus has presented Non-GAAP Operating Expense which is calculated as GAAP Operating Expense excluding: (i) settlement payment from Daewoong (ii) stock-based compensation expense, (iii) revaluation of contingent royalty obligations, (iv) depreciation and amortization and (v) litigation settlement.

Management believes that non-GAAP Operating Expense is useful in helping to identify the company's core operating performance and enables management to consistently analyze the period-to-period financial performance of the core business operations. Management also believes that non-GAAP Operating Expense will enable investors to assess the company in the same way that management assesses the company's current and future operations. The company's definitions of Non-GAAP Operating Expense has limitations as an analytical tool and may differ from other companies reporting similarly named measures. Non-GAAP Operating Expense should be considered in addition to results prepared in accordance with GAAP but should not be considered a substitute for or superior to GAAP results.

(in millions)	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021	
GAAP Operating Expenses	\$25.3	\$38.3	\$38.3	\$32.0	\$133.9	\$27.9	\$26.7	\$26.4	\$128.6	\$209.6	\$4.2	
GAAP (Loss) Income from Operations	(\$25.3)	(\$36.0)	(\$25.1)	(\$12.5)	(\$98.9)	(\$17.4)	(\$18.9)	(\$8.8)	(\$108.0)	(\$153.1)	\$8.0	
GAAP Net (Loss) Income	(\$11.0)	(\$37.6)	(\$27.0)	(\$14.5)	(\$90.0)	(\$19.7)	(\$21.1)	(\$11.5)	(\$110.7)	(\$163.0)	\$6.4	
Adjustments:												
Settlement Payment from Daewoong	-	-	-	-	-	-	-	-	-	-	(\$25.5)	
Stock-based compensation	\$2.0	\$2.5	\$2.5	\$2.5	\$9.5	\$2.6	\$2.4	\$3.0	\$2.6	\$10.6	\$1.6	
Revaluation of contingent royalty obligation	\$4.9	\$1.3	\$1.8	(\$3.8)	\$4.2	(\$9.9)	\$2.4	\$(2.5)	\$7.9	(\$2.0)	\$1.3	
Depreciation and amortization	\$0.5	\$1.0	\$1.2	\$1.5	\$4.1	\$1.8	\$1.7	\$1.7	\$1.9	\$7.0	\$2.0	
Litigation settlement	-	-	-	-	-	-	-	-	\$83.4	\$83.4	-	
Non-GAAP Operating Expense	\$17.9	\$33.6	\$32.8	\$31.8	\$116.1	\$33.4	\$20.2	\$24.2	\$32.8	\$110.6	\$24.8	
Non-GAAP Loss From Operations	\$17.9	\$31.3	\$19.6	\$12.4	\$81.1	\$22.9	\$12.4	\$6.5	\$12.2	\$54.0	\$12.6	
Non-GAAP Net Loss	\$3.6	\$32.9	\$21.5	\$14.3	\$72.2	\$25.2	\$14.7	\$9.2	\$14.9	\$64.0	\$14.2	



19

Important Safety Information

IMPORTANT SAFETY INFORMATION FOR JEUVEAU® (prabotulinumtoxinA-xvfs)

JEUVEAU may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of JEUVEAU:

- Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.
- Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site
 and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision,
 blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly,
 loss of bladder control, trouble breathing, trouble swallowing.

Do not use JEUVEAU if you: are allergic to any of the ingredients in JEUVEAU (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as rimabotulinumtoxinB (MYOBLOC[®]), onabotulinumtoxinA (BOTOX[®]/BOTOX[®] Cosmetic), abobotulinumtoxinA (DYSPORT[®]), or incobotulinumtoxinA (XEOMIN[®]); have a skin infection at the planned injection site; or are a child.

JEUVEAU dosing units are not the same as, or comparable to, any other botulinum.

Tell your healthcare provider about all your muscle or nerve conditions, such as ALS or Lou Gehrig's disease, Myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects including difficulty swallowing and difficulty breathing from typical doses of JEUVEAU.

Tell your healthcare provider about all your medical conditions, including: any side effects from botulinum toxin products, including dry eye; breathing, swallowing, bleeding, or heart problems; plans to have surgery; weakness of forehead muscles; drooping eyelids; had surgery on your face; are pregnant or breastfeeding or plan to become pregnant or breastfeed (it is not known if JEUVEAU can harm your unborn baby or passes into breast milk).

Tell your healthcare provider about all the medicines you take, including prescription and over-thecounter medicines, vitamins, and herbal supplements. Using JEUVEAU with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your healthcare provider that you have received JEUVEAU in the past. Especially tell your healthcare provider if you: have received any other botulinum toxin product in the past and the last 4 months. and exactly which product you received (such as BOTOX, BOTOX Cosmetic, MYOBLOC, DYSPORT, or XEOMIN).

JEUVEAU may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of treatment with JEUVEAU. If this happens, do not drive a car, operate machinery, or do other dangerous activities.

JEUVEAU can cause other serious side effects including: allergic reactions (such as itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint), heart problems (such as irregular heartbeat and heart attack), and eye problems (including dry eye, reduced blinking, and corneal problems). Tell your healthcare provider or get medical emergency help right away if you experience a serious side effect.

The most common side effects include: headache; eyelid drooping, upper respiratory tract infection, and increased white blood cell count in your blood.

APPROVED USE

JEUVEAU is a prescription medicine that is injected into muscles and used in adults for a short period of time (temporary) to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines).

The risk information provided here is not complete. For more information about JEUVEAU, see the full <u>Prescribing</u> <u>Information including BOXED WARNING</u>, and <u>Medication Guide</u>, visit <u>evolus.com</u> or talk to your healthcare provider.

Exclusively licensed and manufactured for: Evolus, Inc., 520 Newport Center Drive, Suite 1200, Newport Beach, CA 92660

©2021 Evolus, Inc. All rights reserved. JEUVEAU is a registered trademark of Evolus, Inc. All other trademarks are the property of their respective owners.



